From the Journals

Resistant hypertension hits SLE patients hard


 

FROM ARTHRITIS CARE & RESEARCH

Patients with systemic lupus erythematosus (SLE) were 72% more likely to have resistant hypertension than were control patients at a tertiary care center.

wildpixel/Thinkstock

A patient with resistant hypertension either has blood pressure remaining above 140/90 mm Hg while taking three antihypertensive medications or requires the use of four or more antihypertensives to attain blood pressure control. Resistant hypertension, which was more likely to occur among blacks and patients with lower renal function, hypercholesterolemia, and increased inflammatory markers, increased the risk of death nearly threefold (hazard ratio, 2.91; P = .0005) when compared with those who didn’t have this condition.


The results of this analysis were published March 15 in Arthritis Care & Research (doi: 10.1002/acr.23880). We covered this study at the 2018 annual meeting of the American College of Rheumatology in Chicago before it was published in the journal. Read our previous story at the link above.

Recommended Reading

ACR CRISS: A way forward for scleroderma treatment trials?
MDedge Dermatology
Three drugs disappoint in SSc trials, but show some promise
MDedge Dermatology
RELIEF: In Behçet’s, apremilast improves oral ulcers for up to 28 weeks
MDedge Dermatology
Combination immunotherapy ups survival in ILD patients with anti-MDA5–positive dermatomyositis
MDedge Dermatology
Increased cancer risk in dermatomyositis has temporal limits
MDedge Dermatology
Novel SSc classification scheme aims to improve risk stratification
MDedge Dermatology
Tofacitinib tackles cutaneous sarcoidosis
MDedge Dermatology
New findings raise questions about the role of ANAs in SLE
MDedge Dermatology
List of medications linked to drug-induced lupus expands
MDedge Dermatology
BTK inhibitor calms pemphigus vulgaris with low-dose steroids
MDedge Dermatology